Introduction
Pharmaceutical product authorization and market access in Turkey is a highly regulated legal field that determines whether a human medicinal product may be placed on the Turkish market, sold through lawful channels, priced, reimbursed, promoted, monitored and supplied to patients. Turkey has a detailed pharmaceutical regulatory framework administered mainly by the Turkish Medicines and Medical Devices Agency, known as TİTCK, together with the Ministry of Health and the Social Security Institution, known as SGK.
For pharmaceutical companies, marketing authorization holders, importers, distributors, manufacturers, foreign investors and healthcare lawyers, market access in Turkey is not limited to obtaining a product license. A medicine may receive marketing authorization but still face pricing delays, reimbursement challenges, supply restrictions, pharmacovigilance obligations, inspection risks, promotional limitations or post-market recall duties. Therefore, market access must be understood as a complete regulatory pathway from product classification to commercial launch and post-market compliance.
The core regulatory instrument for human medicinal product authorization is the Regulation on Marketing Authorization of Human Medicinal Products. Its purpose is to determine procedures and principles for authorization processes and post-authorization practices in order to ensure that human medicinal products have the required quality, efficacy and safety. The regulation applies to industrially prepared human medicinal products or products manufactured through an industrial process, as well as applicants and authorization holders.
Legal Framework for Pharmaceutical Authorization in Turkey
Pharmaceutical authorization in Turkey is based on several layers of law and regulation. The most important framework includes the Regulation on Marketing Authorization of Human Medicinal Products, Law No. 1262 on Pharmaceutical and Medical Preparations, TİTCK guidelines, pricing legislation, pharmacovigilance rules, product promotion rules, market control rules, product recall rules and SGK reimbursement regulations.
TİTCK’s official regulatory ecosystem includes legislation, systems, lists and documents concerning medicines, pricing, pharmacovigilance, product safety, recalls, electronic applications, medicine tracking, licensed products, product information and pharmaceutical warehouses. TİTCK’s official page lists, among others, the Electronic Application System, İlaç Takip Sistemi, Reçetem System, Ruhsatlı Ürünler Listesi, KÜB/KT Listesi, Detaylı İlaç Fiyat Listesi and Referans Bazlı İlaç Fiyat Listesi.
This means that pharmaceutical market access in Turkey should be analyzed through both legal and operational compliance. A company must not only satisfy the legal conditions of authorization but also use the correct electronic systems, pay applicable fees, maintain updated product information, comply with price lists and monitor current TİTCK and SGK announcements.
What Is Marketing Authorization?
Marketing authorization is the administrative approval allowing a pharmaceutical product to be placed on the Turkish market as a human medicinal product. Without authorization, a product cannot normally be commercialized as a medicine in Turkey. Authorization confirms that the competent authority has evaluated the product’s quality, safety and efficacy within the applicable legal framework.
Under the Turkish authorization regulation, the licensing regime is designed to ensure that human medicinal products meet desired standards of efficacy, safety and quality. The regulation also identifies specific sections for marketing authorization obligation, application form, persons who may apply, documents required for authorization applications and different application pathways such as informed consent applications, well-established medicinal use, generic medicinal products, hybrid applications, biosimilars and fixed-combination products.
From a legal perspective, authorization is not merely a commercial permit. It is a public health decision. The authorization holder assumes continuing responsibility for the product after approval, including pharmacovigilance, quality compliance, variation applications, product information updates, batch-related obligations and post-market safety measures.
Product Classification Before Market Entry
The first step in market access is correct product classification. A product may fall under different legal categories, including human medicinal product, traditional herbal medicinal product, homeopathic product, special medical purpose food, food supplement, cosmetic product, medical device or biocidal product. Classification determines which regulatory pathway applies, which authority has jurisdiction, what claims may be made, whether clinical or quality data are required, and whether the product can be sold through pharmacies or other channels.
This stage is critical because incorrect classification may cause delays, rejection, sanctions or unlawful market activity. A product advertised as a supplement may actually be considered a medicinal product if it is presented as treating or preventing disease. A cosmetic product may become legally problematic if promoted with therapeutic claims. A medical device may require product tracking and conformity rules rather than medicine authorization.
For foreign companies, classification should be reviewed before importing samples, preparing Turkish labels, signing distribution agreements or launching marketing campaigns. A market access plan based on the wrong classification may collapse at the first regulatory review.
Who Can Apply for Pharmaceutical Authorization in Turkey?
Marketing authorization applications must be submitted by legally eligible applicants. In practice, applicants are usually pharmaceutical companies, importers, manufacturers or local representatives that satisfy Turkish regulatory requirements. The authorization holder must be able to communicate with TİTCK, submit data, maintain documentation, manage pharmacovigilance, respond to product safety issues and fulfill post-authorization obligations.
The Regulation on Marketing Authorization of Human Medicinal Products contains a specific provision on who may submit authorization applications and another provision on required information and documents. It also includes different application types for various regulatory pathways, such as generic, biosimilar, hybrid and fixed-combination applications.
For foreign companies, a local regulatory strategy is usually essential. Turkey-specific requirements, local representative issues, Turkish-language product information, electronic application systems, GMP documentation, pricing procedures and reimbursement strategy should be planned before submission.
The Role of TİTCK Electronic Application Systems
TİTCK’s digital infrastructure plays a major role in pharmaceutical authorization. TİTCK’s official resources refer to the Electronic Application System and important documents such as the İlaç Ruhsatlandırma Dairesi Sıkça Sorulan Sorular and Başvurularda Dikkat Edilmesi Gereken Hususlar. These resources show that product authorization is managed through structured institutional systems and formal application standards.
Electronic application compliance is important because an incomplete, inconsistent or improperly formatted submission may delay evaluation. Market access teams must ensure that all required modules, forms, administrative documents, quality data, clinical/non-clinical information, product information, pharmacovigilance materials and manufacturing site documentation are properly submitted.
In practice, successful authorization requires both scientific preparation and procedural discipline. A strong dossier can still face delay if administrative requirements are not met. Conversely, a procedurally complete application may fail if quality, safety or efficacy data are insufficient.
Quality, Safety and Efficacy Requirements
The foundation of pharmaceutical authorization is the assessment of quality, safety and efficacy. Quality concerns the product’s composition, manufacturing process, specifications, stability, analytical methods, impurities, packaging and consistency. Safety concerns toxicology, adverse effects, risk management and patient protection. Efficacy concerns whether the product produces the intended therapeutic effect for the proposed indication.
The Turkish authorization regulation expressly frames its purpose around ensuring that human medicinal products have the required quality, efficacy and safety. This means that companies must prepare a dossier capable of supporting the product’s benefit-risk balance.
For generic products, the focus may include bioequivalence and pharmaceutical equivalence. For biosimilars, comparability and biological complexity become central. For innovative medicines, clinical data, non-clinical data and risk management are usually more extensive. For fixed-combination products, justification of combined use and therapeutic rationale may be required.
GMP and Manufacturing Site Compliance
Good Manufacturing Practice, known as GMP, is a key condition for pharmaceutical market access. A medicine cannot be treated only as a formula or active substance. It must be manufactured in a facility that satisfies quality and regulatory standards. Manufacturing site compliance is especially important for imported products, because TİTCK may evaluate foreign manufacturing sites and require proper GMP evidence.
TİTCK’s official resources include lists of domestic facilities subject to institutional inspection and lists of foreign production facilities inspected by the institution for several years. This demonstrates that manufacturing site compliance and inspection are part of the broader market access framework.
For companies, GMP planning should begin early. A product authorization strategy may fail if the manufacturing site cannot satisfy TİTCK expectations, if documentation is incomplete or if inspection findings remain unresolved. GMP compliance should therefore be treated as a core legal and commercial issue, not merely a technical quality department matter.
Product Information: SmPC, Leaflet and Labeling
Market authorization in Turkey also requires approved product information. The Turkish equivalents of the Summary of Product Characteristics and Patient Leaflet are generally referred to as Kısa Ürün Bilgisi and Kullanma Talimatı, commonly abbreviated as KÜB/KT. TİTCK’s official page lists the KÜB/KT Listesi among important medicine lists.
Product information is legally important because it defines how the medicine may be prescribed, used, warned about and promoted to healthcare professionals. Indications, dosage, contraindications, interactions, pregnancy/lactation warnings, adverse effects, storage conditions and pharmacological information must be accurate and approved.
Labeling and leaflet errors can create serious risk. If the Turkish leaflet does not properly warn patients, if the label contains incorrect storage information, or if promotional claims exceed approved product information, the authorization holder may face regulatory consequences. For market access, product information should be prepared carefully and aligned with TİTCK expectations.
Pricing as a Market Access Step
Obtaining marketing authorization does not automatically mean commercial success. A pharmaceutical product also needs an approved price or applicable price status under Turkish rules. TİTCK’s official page publishes annual institutional fee tariffs and includes important lists such as the Detaylı İlaç Fiyat Listesi and Referans Bazlı İlaç Fiyat Listesi.
Pricing is a central part of market access because it affects launch timing, profitability, distribution, reimbursement negotiations and patient access. Turkey uses a regulated medicine pricing system, and companies must evaluate reference pricing, currency rules, price applications and official list updates.
A product with marketing authorization but without a commercially viable price may not effectively enter the market. Therefore, companies should consider pricing strategy during the authorization process, not after approval. Pricing, reimbursement and supply planning must be integrated.
SGK Reimbursement and Public Market Access
In Turkey, market access is strongly connected to SGK reimbursement. A medicine may be authorized and priced, but if it is not reimbursed, patient access and commercial volume may remain limited. SGK publishes frequent updates to the Bedeli Ödenecek İlaçlar Listesi, including medicines added, amended, activated or removed from reimbursement lists.
SGK’s announcement page showed multiple June 2026 updates, including the 24 June 2026 “Bedeli Ödenecek İlaçlar Listesinde Yapılan Düzenlemeler Hakkında Duyuru 2026/24,” as well as related June 2026 announcements on reimbursable medicines and medicine supply source lists. SGK’s 10 June 2026 announcement stated that changes to the reimbursable medicines list were made under the SGK Drug Reimbursement Regulation and SUT provisions, with annexes covering medicines added, amended, activated and removed from EK-4/A.
For pharmaceutical companies, this means that reimbursement strategy must be planned separately from authorization strategy. A product should be evaluated for clinical value, budget impact, comparator products, treatment pathway, unmet medical need, alternative therapies, SGK criteria and possible risk-sharing or special access considerations.
Difference Between Authorization, Pricing and Reimbursement
A common mistake is assuming that authorization, pricing and reimbursement are the same step. They are separate but connected stages.
Authorization means the product may legally be placed on the Turkish market as a medicinal product. Pricing determines the official or applicable price framework. Reimbursement determines whether SGK will pay for the product, under what conditions and for which patients.
A medicine can be authorized but not reimbursed. A medicine can be reimbursed only for limited indications. A medicine can be reimbursed with medical report requirements, specialist physician restrictions, dose limits or patient eligibility conditions. For companies, each stage must be handled with separate evidence, strategy and documentation.
Importation and Foreign Product Market Access
Imported medicines require additional planning. Foreign authorization, manufacturing site compliance, GMP documentation, Turkish product information, local representation, batch release, customs, storage and distribution channels must be assessed. Importing a product without proper regulatory status may create legal risk even if the product is authorized in another country.
Turkey may also have special mechanisms for unavailable or foreign-sourced medicines in certain circumstances, but these mechanisms should not be confused with ordinary commercial market authorization. A product supplied under exceptional foreign medicine procedures is not necessarily the same as a fully authorized and commercially launched product.
Foreign companies should avoid informal importation, promotional pre-launch activity and unauthorized supply structures. Turkish market entry should be built on a lawful authorization and access strategy.
Pharmacovigilance Obligations
Market access does not end when the product reaches patients. Authorization holders must maintain pharmacovigilance systems to monitor adverse effects and product safety. TİTCK’s official resources include İlaç Yan Etki Bildirimi, TÜFAM, risk management materials, doctor information letters and lists related to additional monitoring and medicine safety.
Pharmacovigilance obligations may include adverse event reporting, periodic safety reporting, risk management plans, signal detection, safety communication, product information updates and cooperation with TİTCK. These obligations are especially important for new medicines, biological products, products under additional monitoring and medicines with significant safety concerns.
A weak pharmacovigilance system can jeopardize the product’s market position. If the authorization holder fails to detect, report or manage safety risks, regulatory action may follow. Pharmacovigilance should therefore be integrated into the company’s Turkish compliance program before launch.
Post-Market Surveillance and Product Safety
TİTCK has an active role in market control and product safety. Its official resources include links and lists concerning unsafe products, risk management materials, doctor information letters, product warnings and market-related updates.
Post-market surveillance may involve sampling, laboratory testing, batch review, complaint investigation, product defect assessment, market withdrawal, public announcements and recall procedures. Authorization holders must respond quickly to any safety or quality signal.
For pharmacies and distributors, post-market safety measures may require stock blocking, product return, patient communication or supply interruption. For authorization holders, failure to manage post-market safety properly can result in sanctions, reputational harm and possible civil liability.
Product Recalls and Market Withdrawal
Product recall is a key part of pharmaceutical market access compliance. A recall may occur due to quality defects, contamination, incorrect labeling, stability problems, manufacturing errors, pharmacovigilance concerns or regulatory non-compliance. Once a recall decision is made, the authorization holder and supply chain actors must act quickly.
TİTCK’s official resources include links to public announcements, doctor information letters, risk management materials and safety-related documents. These resources reflect the practical importance of safety communication and product risk management.
A company entering the Turkish market should have a recall procedure before launch. The procedure should identify responsible persons, communication channels, warehouse coordination, pharmacy notification methods, batch tracking, documentation, timelines and reporting to TİTCK.
Promotion and Market Access
Promotion is another major issue. A pharmaceutical product may be authorized, priced and reimbursed, but promotional activities remain strictly regulated. Medicines cannot be promoted to the public in the same way as ordinary consumer products. Promotion to healthcare professionals must comply with pharmaceutical promotion rules, approved product information and ethical standards.
TİTCK’s official resources include materials on promotional activities and value transfer systems. Companies must ensure that sales teams, medical science liaisons, marketing departments and distributors understand the limits of Turkish promotional law.
Pre-authorization promotion is particularly risky. A product that has not yet received authorization should not be commercially promoted as if it were available. Promotional claims must not exceed the approved indication, dosage or product information. Scientific exchange should not be used as disguised advertising.
Distribution and Supply Chain Compliance
After authorization, a pharmaceutical product must move through lawful distribution channels. Pharmaceutical warehouses, pharmacies, hospitals and other supply chain actors must comply with Turkish medicine supply rules. TİTCK’s official lists include pharmaceutical warehouse lists and medicine tracking system links.
Supply chain compliance includes storage conditions, cold-chain management, batch traceability, returns, recalls, counterfeit medicine prevention, stock monitoring and record-keeping. A product may lose legal and commercial value if the supply chain cannot preserve quality.
For market access, distribution agreements should address regulatory responsibilities, storage standards, recall cooperation, pharmacovigilance reporting, reporting duties, confidentiality, audit rights and termination in case of non-compliance.
İlaç Takip Sistemi and Traceability
The İlaç Takip Sistemi, or İTS, is essential for medicine traceability in Turkey. TİTCK’s official page links to the İTS platform among its main institutional systems.
For authorization holders and market participants, İTS compliance supports lawful product movement, prevention of counterfeit medicines, recall implementation, reimbursement integrity and stock control. Market access planning should include serialization, barcode, system integration and supply chain readiness.
If a product cannot be properly tracked through required systems, commercial launch may face operational problems. İTS readiness should therefore be reviewed before importation, distribution and pharmacy supply.
Special Categories: Generics, Biosimilars and Biologics
Different product types require different authorization strategies. Generic medicines usually rely on reference product data and bioequivalence. Biosimilars require comparability and careful scientific justification due to biological complexity. Biologics, blood products, vaccines and advanced therapies may require additional quality, safety, manufacturing and pharmacovigilance scrutiny.
The Regulation on Marketing Authorization of Human Medicinal Products expressly identifies application categories such as generic medicinal product applications, hybrid applications, biosimilar medicinal product applications and fixed-combination applications.
Companies should choose the correct pathway from the beginning. Submitting a dossier under the wrong legal category may cause delay, additional data requests or refusal.
Data Exclusivity and Regulatory Strategy
Market access also requires review of data exclusivity, reference product status, patent considerations, trademark issues and regulatory protection. Generic and biosimilar strategies must be coordinated with intellectual property analysis. Authorization may be a regulatory issue, but commercial launch may also depend on patent litigation, preliminary injunction risk, pricing position and reimbursement timing.
A company planning a generic or biosimilar launch should conduct legal due diligence on reference product protection, patent expiry, supplementary protection issues if relevant, trademark clearance and unfair competition risks. Regulatory approval does not automatically eliminate private-law obstacles.
Common Market Access Mistakes
The first common mistake is treating authorization as the final step. In Turkey, authorization must be followed by pricing, reimbursement, distribution and post-market compliance.
The second mistake is ignoring classification. A product presented with therapeutic claims may be treated as a medicine even if the company planned to sell it as a supplement or cosmetic.
The third mistake is preparing a global dossier without Turkey-specific adaptation. Turkish-language product information, local administrative documents, electronic systems and national requirements must be addressed.
The fourth mistake is delaying reimbursement strategy until after authorization. SGK access may determine commercial success.
The fifth mistake is failing to build pharmacovigilance, recall and İTS readiness before launch.
Practical Market Access Checklist
A company seeking pharmaceutical market access in Turkey should follow a structured checklist.
First, classify the product correctly. Second, identify the regulatory pathway. Third, confirm applicant eligibility and local representation. Fourth, prepare the authorization dossier according to Turkish requirements. Fifth, review GMP and manufacturing site compliance. Sixth, prepare Turkish product information, labeling and leaflet materials. Seventh, submit through the correct TİTCK systems. Eighth, plan price application and reimbursement strategy. Ninth, evaluate SGK listing requirements and potential SUT restrictions. Tenth, prepare pharmacovigilance, distribution, İTS, recall and promotion compliance procedures before launch.
This checklist should be adapted for each product type, especially generics, biosimilars, orphan-like products, high-cost therapies, imported medicines and products requiring cold-chain logistics.
Frequently Asked Questions
What is pharmaceutical product authorization in Turkey?
It is the TİTCK approval process allowing a human medicinal product to be legally placed on the Turkish market after assessment of quality, safety and efficacy under the applicable authorization regulation.
Is marketing authorization enough for commercial launch?
No. A company must also consider pricing, reimbursement, distribution, İTS traceability, pharmacovigilance, promotion restrictions and post-market obligations.
Which authority regulates medicines in Turkey?
The main authority is TİTCK. Its official resources include legislation, electronic application systems, licensed product lists, medicine price lists, pharmacovigilance tools, medicine tracking systems and other pharmaceutical regulatory materials.
How is reimbursement handled?
SGK determines reimbursement through SUT and reimbursable medicine lists. SGK regularly publishes updates on medicines added, amended, activated or removed from reimbursement lists.
Can a foreign company market a medicine in Turkey without Turkish authorization?
As a general rule, commercial market entry as a human medicinal product requires compliance with Turkish authorization rules. Exceptional foreign medicine mechanisms should not be confused with ordinary market authorization.
Conclusion
Pharmaceutical product authorization and market access in Turkey require a complete legal and regulatory strategy. The process begins with product classification and marketing authorization, but it does not end there. A company must also address GMP, product information, pricing, SGK reimbursement, distribution, İTS traceability, pharmacovigilance, promotion restrictions, post-market surveillance and recall readiness.
TİTCK is the central authority for medicine regulation, and its official systems and lists play a major role in daily pharmaceutical compliance. SGK reimbursement is equally important for commercial success because patient access in Turkey is strongly affected by public reimbursement decisions and the Bedeli Ödenecek İlaçlar Listesi.
For pharmaceutical companies, the safest approach is to treat Turkey as a full regulatory market, not merely as a sales destination. A strong Turkish market access plan should combine legal review, scientific dossier preparation, pricing analysis, reimbursement strategy, local compliance systems, supply chain planning and post-market safety procedures.
A product that is authorized but not priced, reimbursed, traceable, safely distributed or properly monitored may fail commercially or face regulatory risk. Conversely, a company that plans authorization and market access together can reduce delay, protect compliance, improve patient access and build a sustainable presence in the Turkish pharmaceutical market.
Yanıt yok